Welcome to our dedicated page for Supernus Pharmaceuticals news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharmaceuticals stock.
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is a leading specialty pharmaceutical company dedicated to developing and commercializing innovative products for the treatment of central nervous system (CNS) disorders. With over two decades of experience in the industry, Supernus has made significant strides in neurology and psychiatry.
Supernus’ product portfolio is diverse, including approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. Flagship products include Trokendi XR®, Oxtellar XR®, Qelbree®, APOKYN®, XADAGO®, MYOBLOC®, GOCOVRI®, and Osmolex ER®.
In 2013, Supernus successfully launched two groundbreaking products: Oxtellar XR® and Trokendi XR®, both aimed at treating epilepsy. These innovative formulations offer extended-release solutions, enhancing patient convenience and compliance.
Beyond these milestones, Supernus is actively developing new therapeutic candidates in psychiatry to address unmet medical needs in ADHD, depression, and their co-existing disorders. The company leverages proprietary and in-licensed technologies to create differentiated products. By focusing on known drug compounds with established mechanisms of action, Supernus minimizes the risks, costs, and time associated with new drug development.
Supernus has recently announced notable developments:
- Financial and business results for Q4 and the full year of 2023 will be reported on February 27, 2024.
- Actress Busy Philipps has partnered with Supernus to raise awareness about ADHD during Mental Health Awareness Month, spotlighting Qelbree® as a non-stimulant medication for ADHD.
- Supernus signed an exclusive licensing agreement with M8 Pharmaceuticals to commercialize Qelbree® in Latin America, expanding its reach and impact.
With a strong foundation and ongoing projects, Supernus Pharmaceuticals continues to make significant contributions to the field of CNS disorders, enhancing patient lives through innovative solutions.
Supernus Pharmaceuticals reported second quarter 2021 revenues of $141.3 million, a 12% increase from the previous year. The launch of Qelbree for pediatric ADHD saw net product sales of $0.3 million. Operating earnings were $34.1 million, down from $45.5 million in 2020. Net earnings and diluted EPS were $23.7 million and $0.43, respectively, compared to $34.7 million and $0.65 a year prior. The company has $855.3 million in cash as of June 30, 2021. Financial guidance for the full year remains unchanged at $550 - $580 million in total revenues.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced it will report its second quarter 2021 financial results on August 4, 2021, after market close. A conference call will be held on the same day at 4:30 p.m. ET, led by CEO Jack Khattar and CFO Jim Kelly, to discuss these results. Attendees can join via dial-in or a live webcast on the company’s website. Supernus specializes in developing treatments for central nervous system diseases and has a diverse portfolio that includes approved medications for conditions like epilepsy and Parkinson's disease.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that CEO Jack Khattar will present a company overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 1:30 p.m. ET. Interested parties can access the live webcast via the company’s Investor Relations page. An archived replay will be available for 60 days post-conference.
Supernus focuses on treatments for central nervous system (CNS) diseases, including epilepsy, migraine, and ADHD among others.
Supernus Pharmaceuticals has announced the availability of its FDA-approved ADHD treatment, Qelbree (viloxazine extended-release capsules), for pediatric patients aged 6 to 17. This non-stimulant medication has shown efficacy in improving ADHD symptoms as early as the first week of treatment. Alongside its launch, Supernus has implemented comprehensive patient support programs, including co-pay assistance and a sampling initiative. The company plans to submit a supplemental New Drug Application for Qelbree's use in adults in Q3 2021.
Supernus Pharmaceuticals (SUPN) reported Q1 2021 total revenues of $130.9 million, a 38% increase from Q1 2020. Net product sales totaled $128.4 million, up 39% year-over-year, driven by Trokendi XR and Oxtellar XR. The FDA approved Qelbree for pediatric ADHD, with a planned launch in Q2 2021 and an sNDA for adults anticipated in Q3 2021. Operating earnings were $13.2 million, down from $29.0 million in the previous year. The company has $807.7 million in cash and reiterates its full-year revenue guidance of $550 - $580 million.
Supernus Pharmaceuticals (Nasdaq: SUPN) has reported that Newron Pharmaceuticals has received a Paragraph IV Notice Letter from Aurobindo Pharma regarding its application for safinamide tablets. This letter targets three XADAGO patents expiring between June 2027 and December 2028. Supernus holds a license agreement with Zambon S.p.A. concerning these patents. The company is reviewing the Notice Letter details to safeguard its intellectual property rights related to XADAGO, which is under FDA exclusivity until March 21, 2022.
Supernus Pharmaceuticals (Nasdaq: SUPN) will announce its Q1 2021 results on May 5, 2021, after market close. The conference call, led by CEO Jack Khattar and CFO Jim Kelly, is scheduled for 4:30 p.m. ET that day, with a live webcast available on the company’s website. Supernus specializes in CNS diseases, offering treatments for several conditions, including epilepsy and ADHD. The company is also developing new products aimed at various CNS disorders. Further details can be found in the Investor Relations section of their website.
Supernus Pharmaceuticals announced FDA approval for Qelbree (viloxazine extended-release capsules), a new non-stimulant treatment for ADHD in pediatric patients aged 6-17. This marks a decade's first introduction of such an option. Qelbree is designed to provide a significant alternative for ADHD management, enhancing treatment accessibility without the risks associated with controlled substances. The product is expected to be available in the U.S. by Q2 2021, and a supplemental application for adult usage is anticipated in late 2021.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced Jack Khattar, President and CEO, will participate in a fireside chat at the Cowen 41st Annual Health Care Conference on March 3, 2021, at 12:20 p.m. ET. A live webcast will be available on the Company's website, and an archived replay will be accessible for 60 days after the event. Supernus focuses on developing treatments for central nervous system diseases, including epilepsy and migraines, and is expanding its portfolio to address ADHD and other CNS disorders.
For full year 2020, Supernus Pharmaceuticals reported total revenues of $520.4 million, a 32% increase from 2019, with operating earnings at $173.7 million, up 17%. Q4 2020 net product sales reached $140.7 million, a 44% year-over-year increase. The firm anticipates 2021 total revenues between $550 million and $580 million. SPN-812, for ADHD, is expected to launch in Q2 2021 pending FDA approval. Positive results for SPN-812's Phase III study were reported in December 2020, while SPN-830 awaits further FDA discussions.
FAQ
What is the current stock price of Supernus Pharmaceuticals (SUPN)?
What is the market cap of Supernus Pharmaceuticals (SUPN)?
What types of disorders does Supernus Pharmaceuticals focus on?
What are some of the key products developed by Supernus Pharmaceuticals?
What recent collaborations has Supernus Pharmaceuticals announced?
When will Supernus Pharmaceuticals report its financial results for Q4 and the full year of 2023?
What is the significance of Qelbree®?
How does Supernus Pharmaceuticals leverage its proprietary technologies?
What is the main focus of Supernus Pharmaceuticals' ongoing projects?
Who are the key executives at Supernus Pharmaceuticals?
What are the safety concerns related to Qelbree®?
Where can I find more information about Supernus Pharmaceuticals and its products?
